En Ru

Medicines of the Future Today
Press Room

Petrovax completes government contract for supply of Grippol Plus anti-flu vaccine

15.10.2015

NPO Petrovax Pharm is the first manufacturer of anti-flu vaccines to complete its shipments of Grippol Plus vaccine used to prevent flu in children and pregnant women under the National Immunisation Schedule. Vaccine shipments to Russian regions totalled more than 13.8 million doses.

Given the need to start anti-flu vaccination early, Petrovax Pharm commenced shipments in July 2015 completing them by now in accordance with the approved government contract schedule. The Company’s effort helped all the participating regions to launch the vaccination campaign for children and pregnant women in August, before the onset of the epidemic season. Early immunisation contributes greatly to the efficient reduction of ARVI and flu infection rates among the most susceptible population groups.

It stands to note that Grippol Plus has been successfully used under the National Immunisation Schedule since 2009 to vaccinate pregnant women and children from six months. A total of more than 100 million people have been vaccinated so far. Grippol Plus is the only vaccine used under the government immunisation programme that is shipped in disposable syringes and has no preservatives. The vaccine contains purified antigens of flu strains as per recommendations of the World Health Organisation for the current epidemic season.

As a pioneer of the Russian anti-flu vaccine market, NPO Petrovax Pharm is one of the leading manufacturers and suppliers under the National Immunisation Schedule for Russia and EurAsEC nations.

"We are proud to have been supplying the most advanced forms of anti-flu vaccines nationwide for years now. The Grippol vaccines came as a breakthrough for the Russian immunobiology. Over the 20 years of practical application, they have proved to be highly efficient and safe for the purpose of mass immunisation. Today Grippol and Grippol Plus are justifiably the best Russian anti-flu vaccines," said Arkady Nekrasov, Chairman of the Board of Directors at NPO Petrovax Pharm.

"NPO Petrovax Pharm cherishes its reputation as a reliable partner to the Russian Ministry of Health, so we are particularly scrupulous about fulfilling our obligations under a government contract. If needed, our capacities make it possible to ramp up production and cover 100% of the government's demand for an anti-flu vaccine produced in line with the Russian and international GMP standards," commented Elena Arkhangelskaya, President of NPO Petrovax Pharm.

About Grippol® Plus

Grippol® Plus is a Russian latest-generation adjuvanted subunit preservative-free inactivated influenza vaccine used for flu prevention in adults and children, including babies starting from 6 months of age, pregnant women, and people with chronic somatic diseases. The composition of the vaccine for use in the upcoming influenza season is changed annually as per WHO recommendations. It is made at a modern production facility in compliance with Russian and international GMP standards. Due to its strong efficacy, high quality and safety profile, the Grippol Plus vaccine is exported to a number of CIS countries. Apart from Belarus, Grippol Plus is registered for use in Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine. In the short-term, the Company plans to license the vaccine for sale in Uzbekistan, with the next step being a foray into EU, Middle East, and Latin America markets.

About NPO Petrovax Pharm

NPO Petrovax Pharm is a Russian pharmaceutical company that develops and produces innovative medicines and vaccines. The main activities of the company include: the production of influenza and pneumococcal vaccines for the National Immunisation Schedule, development and production of immunobiological medicines. The company operates in the Moscow Region in full compliance with international standards of GMP EU and ISO 9001 and employs over 600 people. NPO Petrovax Pharm's majority shareholder is a company of Vladimir Potanin, owner and founder of Interros Group.

Media contacts:

Anna Emtsova
+7 495 984 2753, ext. 120 

All news